News

Yumanity Therapeutics, a new biotechnology company working on the development of drug discoveries for the treatment of conditions caused by protein misfolding, was launched last Monday by well-known leader in the biotech industry Tony Coles, M.D., who is not only the founding investor of the company, but will also serve as its chairman and chief…

A new study entitled “Aggregation propensities of Superoxide Dismutase G93 hotspot mutants mirror Amyotrophic Lateral Sclerosis clinical phenotypes” identified a mechanism that leads to the aggregation of SOD protein mutant forms that are typically found in Amyotrophic lateral sclerosis (ALS) motor neurons. The study opens new therapeutic avenues…

Chemists from Cornell University, using a technique that illuminates very subtle changes in individual proteins, may have found new evidence about the underlying causes of Amyotrophic Lateral Sclerosis (ALS). Professor of chemical biology and chemistry Brian Crane led a study and co-authored a follow-up based on a spectroscopic method that is…

New research at Washington University School of Medicine in St. Louis and Cedars-Sinai Medical Center in Los Angeles indicates that genetic mutations may underlie more amyotrophic lateral sclerosis (ALS) than scientists had previously realized. The research results also revealed that the quantity of mutated genes influences at what age…

According to a July 2014 report in the Morbidity and Mortality Weekly Report (MMWR), amytrophic lateral sclerosis (ALS) or Lou Gehrig’s disease is estimated to affect about 3.9 individuals for every 100,000 Americans, most commonly diagnosed in the elderly who are in their 70s. While the cause…

A new study entitled “Angiotensin-Converting Enzyme Inhibitors and Amyotrophic Lateral Sclerosis Risk A Total Population–Based Case-Control Study” reports that using angiotensin-converting enzyme inhibitors (ACEIs) significantly decreases the risk for developing amyotrophic lateral sclerosis. The study was published in the journal Jama Neurology. Amyotrophic lateral sclerosis (ALS), also…

Active Biotech, a Sweden-based biopharmaceutical company that is developing therapies for autoimmune diseases, inflammatory diseases, and cancers, recently announced that it is partnering with Teva Pharmaceutical Industries Ltd. to develop a new, experimental drug for treating Huntington’s disease. The two companies will work together to launch a new phase 2 clinical trial…

Nonsense mutation Duchenne muscular dystrophy (nmDMD) patients living in the European Union may soon experience relief from their condition due to the European Commission granting PTC Therapeutics, Inc. conditional marketing for Translarna™ (ataluren). PTC Therapeutics may now market Translarna in the 28 Member States of…